Home > News > Investors Turn On Patent-Challenged Tessera
March 4th, 2008
Investors Turn On Patent-Challenged Tessera
Abstract:
Tessera Technologies took a beating from investors on Tuesday after the Patent Office rejected one of its key patents.
San Jose-based Tessera Technologies (nasdaq: TSRA - news - people ) said the U.S. Patent and Trademark Office rejected its already heavily licensed 627 patent. The nanotechnology company said the "issued patent is presumed to be valid, intact and enforceable" while it appeals the ruling, a process that takes twenty-four months on average. Investors were shaken by the tainted patent. The company fell 39.0%, or $8.99, to close at $14.07.
On Feb. 29, the Patent Office rejected every tenet of the patent. Competitor Siliconware had sought a reevaluation of five lucrative Tessera patents. This group of patents have been challenged in litigation before. Tessera has reported that the contentious patents have resulted in more than $250 million in cumulative licensing earnings.
Source:
forbes.com
Bookmark:
| Related News Press |
News and information
Decoding hydrogen‑bond network of electrolyte for cryogenic durable aqueous zinc‑ion batteries January 30th, 2026
COF scaffold membrane with gate‑lane nanostructure for efficient Li+/Mg2+ separation January 30th, 2026
Investments/IPO's/Splits
Daikin Industries becomes OCSiAl shareholder July 27th, 2021
INBRAIN Neuroelectronics raises over €14M to develop smart graphene-based neural implants for personalised therapies in brain disorders March 26th, 2021
180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021
Chip Technology
Metasurfaces smooth light to boost magnetic sensing precision January 30th, 2026
Beyond silicon: Electronics at the scale of a single molecule January 30th, 2026
Lab to industry: InSe wafer-scale breakthrough for future electronics August 8th, 2025
Announcements
Decoding hydrogen‑bond network of electrolyte for cryogenic durable aqueous zinc‑ion batteries January 30th, 2026
COF scaffold membrane with gate‑lane nanostructure for efficient Li+/Mg2+ separation January 30th, 2026
Patents/IP/Tech Transfer/Licensing
Getting drugs across the blood-brain barrier using nanoparticles March 3rd, 2023
Metasurfaces control polarized light at will: New research unlocks the hidden potential of metasurfaces August 13th, 2021
Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda November 27th, 2020
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||